11:58 AM EST - Medexus Pharmaceuticals : Today announced that the American Journal of Hematology has accepted for publication the final study results and analysis of the pivotal phase 3 clinical trial of treosulfan conducted by medac, a strategic partner of Medexus. The publication has undergone full peer review and has already been published online. Medexus Pharmaceuticals
shares T.MDP are trading up $0.11 at $2.18.
